Published in Cancer Res on December 01, 1996
Pancreatic cancer. Lancet (2004) 11.63
Pancreatic cancer. Annu Rev Pathol (2008) 6.96
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature (2008) 5.98
Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11. Cell (2011) 4.41
Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol (2003) 3.40
Recent progress in pancreatic cancer. CA Cancer J Clin (2013) 2.88
The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment. Proc Natl Acad Sci U S A (1998) 2.85
Pancreatic carcinogenesis. Pancreatology (2008) 2.60
Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci U S A (2011) 2.47
Gross chromosomal rearrangements and genetic exchange between nonhomologous chromosomes following BRCA2 inactivation. Genes Dev (2000) 2.47
PancPRO: risk assessment for individuals with a family history of pancreatic cancer. J Clin Oncol (2007) 2.45
Plectin-1 as a novel biomarker for pancreatic cancer. Clin Cancer Res (2010) 2.03
The BRCA2 gene product functionally interacts with p53 and RAD51. Proc Natl Acad Sci U S A (1998) 1.97
Deficiency of human BRCA2 leads to impaired homologous recombination but maintains normal nonhomologous end joining. Proc Natl Acad Sci U S A (2001) 1.97
Rad52 inactivation is synthetically lethal with BRCA2 deficiency. Proc Natl Acad Sci U S A (2010) 1.94
Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterology (2014) 1.78
BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. Am J Pathol (2000) 1.72
Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice. Gastroenterology (2011) 1.70
Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: A newly described and characterized entity. Am J Pathol (2000) 1.69
Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010. World J Gastroenterol (2011) 1.65
High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions. Clin Cancer Res (2013) 1.63
Unraveling the mechanism of BRCA2 in homologous recombination. Nat Struct Mol Biol (2011) 1.59
Current status of molecular markers for early detection of sporadic pancreatic cancer. Biochim Biophys Acta (2010) 1.58
Importance of age of onset in pancreatic cancer kindreds. J Natl Cancer Inst (2010) 1.57
Update on familial pancreatic cancer. Adv Surg (2010) 1.54
Detecting early pancreatic cancer: problems and prospects. Semin Oncol (2007) 1.54
Identifying molecular markers for the early detection of pancreatic neoplasia. Semin Oncol (2007) 1.49
Molecular signatures of pancreatic cancer. Arch Pathol Lab Med (2011) 1.46
Inactivation of Brca2 cooperates with Trp53(R172H) to induce invasive pancreatic ductal adenocarcinomas in mice: a mouse model of familial pancreatic cancer. Cancer Biol Ther (2011) 1.45
BRCA2 is ubiquitinated in vivo and interacts with USP11, a deubiquitinating enzyme that exhibits prosurvival function in the cellular response to DNA damage. Mol Cell Biol (2004) 1.44
Genetic alterations in pancreatic carcinoma. Mol Cancer (2003) 1.43
RAD51C facilitates checkpoint signaling by promoting CHK2 phosphorylation. J Cell Biol (2009) 1.41
Family history is a significant risk factor for pancreatic cancer: results from a systematic review and meta-analysis. Fam Cancer (2008) 1.36
BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J Clin Oncol (2008) 1.36
Genetic susceptibility to pancreatic cancer. Mol Carcinog (2012) 1.36
Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. Nat Genet (2015) 1.34
An absolute risk model to identify individuals at elevated risk for pancreatic cancer in the general population. PLoS One (2013) 1.33
Functional defects in the fanconi anemia pathway in pancreatic cancer cells. Am J Pathol (2004) 1.32
Genetic and epigenetic alterations of familial pancreatic cancers. Cancer Epidemiol Biomarkers Prev (2008) 1.31
Hereditary pancreatic cancer. Gastroenterology (2010) 1.31
Cellular redistribution of Rad51 in response to DNA damage: novel role for Rad51C. J Biol Chem (2009) 1.23
The DNA-damage effector checkpoint kinase 1 is essential for chromosome segregation and cytokinesis. Proc Natl Acad Sci U S A (2009) 1.22
Identifying people at a high risk of developing pancreatic cancer. Nat Rev Cancer (2012) 1.21
Role of BRCA1 and BRCA2 mutations in pancreatic cancer. Gut (2006) 1.19
Recognition of DNA double strand breaks by the BRCA1 tumor suppressor network. Chromosoma (2008) 1.18
Detection of early-stage pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev (2010) 1.17
Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev (2016) 1.13
Serum cadmium levels in pancreatic cancer patients from the East Nile Delta region of Egypt. Environ Health Perspect (2006) 1.11
Aurora-A expressing tumour cells are deficient for homology-directed DNA double strand-break repair and sensitive to PARP inhibition. EMBO Mol Med (2010) 1.08
Germline BRCA2 mutations in men with breast cancer. Br J Cancer (1997) 1.07
Molecular characteristics of pancreatic ductal adenocarcinoma. Patholog Res Int (2011) 1.03
Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection. World J Gastroenterol (2014) 1.03
Pancreatic cancer screening. Gastroenterol Clin North Am (2012) 1.02
A syngeneic variance library for functional annotation of human variation: application to BRCA2. Cancer Res (2008) 1.02
Metabolism addiction in pancreatic cancer. Cell Death Dis (2014) 1.02
The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel. Br J Cancer (2001) 1.01
Elevated cancer mortality in the relatives of patients with pancreatic cancer. Cancer Epidemiol Biomarkers Prev (2009) 1.01
Clinical significance of p16 protein expression loss and aberrant p53 protein expression in pancreatic cancer. Yonsei Med J (2005) 1.00
The complexity of pancreatic ductal cancers and multidimensional strategies for therapeutic targeting. J Pathol (2010) 1.00
Allele-specific expression in the germline of patients with familial pancreatic cancer: an unbiased approach to cancer gene discovery. Cancer Biol Ther (2007) 0.98
BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Genet Med (2014) 0.97
Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. Drug Des Devel Ther (2015) 0.97
Inherited predisposition to pancreatic cancer. Gut (2001) 0.97
Advances in the Genetic Screening, Work-up, and Treatment of Pancreatic Cancer. Curr Treat Options Gastroenterol (2004) 0.96
Current and future systemic treatment options in metastatic pancreatic cancer. J Gastrointest Oncol (2014) 0.95
Endometrial cancer occurence five years after breast cancer in BRCA2 mutation patient. Obstet Gynecol Sci (2015) 0.95
Early detection and prevention of pancreatic cancer: is it really possible today? World J Gastroenterol (2014) 0.95
Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects. World J Gastroenterol (2014) 0.95
Absence of germline BRCA1 mutations in familial pancreatic cancer patients. Cancer Biol Ther (2009) 0.95
FANCD2, FANCJ and BRCA2 cooperate to promote replication fork recovery independently of the Fanconi Anemia core complex. Cell Cycle (2015) 0.95
Incidence of subsequent pancreatic adenocarcinoma in patients with a history of nonpancreatic primary cancers. Cancer (2011) 0.93
BRCA1 and BRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age. J Med Genet (2001) 0.92
BRCA2 coordinates the activities of cell-cycle kinases to promote genome stability. Cell Rep (2014) 0.92
Werner syndrome as a hereditary risk factor for exocrine pancreatic cancer: potential role of WRN in pancreatic tumorigenesis and patient-tailored therapy. Cancer Biol Ther (2010) 0.92
Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance. Cancer Biol Ther (2008) 0.92
Absence of deleterious palladin mutations in patients with familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev (2009) 0.91
Comprehensive genomic analysis of a BRCA2 deficient human pancreatic cancer. PLoS One (2011) 0.91
Inherited pancreatic cancer syndromes. Cancer J (2012) 0.90
Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer. Biomed Res Int (2014) 0.90
Morphogenesis of pancreatic cancer: role of pancreatic intraepithelial neoplasia (PanINs). Langenbecks Arch Surg (2008) 0.90
Using gene carrier probability to select high risk families for identifying germline mutations in breast cancer susceptibility genes. J Med Genet (1998) 0.90
Genetic alterations in pancreatic cancer. World J Gastroenterol (2007) 0.89
Genome-wide somatic copy number alterations in low-grade PanINs and IPMNs from individuals with a family history of pancreatic cancer. Clin Cancer Res (2012) 0.89
Prevalence of BRCA2 and CDKN2a mutations in German familial pancreatic cancer families. Fam Cancer (2010) 0.88
Targeting aberrant DNA double-strand break repair in triple-negative breast cancer with alpha-particle emitter radiolabeled anti-EGFR antibody. Mol Cancer Ther (2013) 0.88
BRCA2 suppresses cell proliferation via stabilizing MAGE-D1. Cancer Res (2005) 0.87
Emerging molecular biology of pancreatic cancer. Gastrointest Cancer Res (2008) 0.87
Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy. Oncologist (2014) 0.87
Genetic inactivation of the Fanconi anemia gene FANCC identified in the hepatocellular carcinoma cell line HuH-7 confers sensitivity towards DNA-interstrand crosslinking agents. Mol Cancer (2010) 0.86
The HsRAD51B-HsRAD51C stabilizes the HsRAD51 nucleoprotein filament. DNA Repair (Amst) (2013) 0.85
Prevalence and characteristics of pancreatic cancer in families with BRCA1 and BRCA2 mutations. Fam Cancer (2008) 0.84
Familial pancreatic carcinoma in Jews. Fam Cancer (2004) 0.83
Family history of cancer and germline BRCA2 mutations in sporadic exocrine pancreatic cancer. Gut (2002) 0.83
Can Molecular Biomarkers Change the Paradigm of Pancreatic Cancer Prognosis? Biomed Res Int (2016) 0.82
Pancreatic cancer genomics: insights and opportunities for clinical translation. Genome Med (2013) 0.82
Genetics and pathology of pancreatic cancer. HPB (Oxford) (2006) 0.82
PARI overexpression promotes genomic instability and pancreatic tumorigenesis. Cancer Res (2013) 0.82
Effects of BRCA2 deficiency on telomere recombination in non-ALT and ALT cells. Genome Integr (2011) 0.82
Genetic alterations during colorectal-tumor development. N Engl J Med (1988) 26.82
Definition of a consensus binding site for p53. Nat Genet (1992) 12.76
New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology (1999) 11.94
DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science (1996) 11.13
The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum (1991) 9.82
Gene expression profiles in normal and cancer cells. Science (1997) 9.65
Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg (1997) 8.86
Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Nature (2000) 8.59
Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg (2001) 8.34
Identification of a chromosome 18q gene that is altered in colorectal cancers. Science (1990) 8.32
Genome of the bacterium Streptococcus pneumoniae strain R6. J Bacteriol (2001) 7.97
Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med (1999) 7.56
Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med (1996) 7.09
Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res (2001) 6.78
Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res (2001) 6.73
Familial breast-ovarian cancer locus on chromosome 17q12-q23. Lancet (1991) 6.61
Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet (1994) 6.50
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst (2000) 6.38
Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nat Genet (2001) 6.36
Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol (2001) 6.30
Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med (2000) 6.27
Assessment of the sensitivity and specificity of oligonucleotide (50mer) microarrays. Nucleic Acids Res (2000) 6.20
Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell (1998) 5.88
One hundred and forty-five consecutive pancreaticoduodenectomies without mortality. Ann Surg (1993) 5.87
Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg (1995) 5.66
Allelotype of colorectal carcinomas. Science (1989) 5.54
Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ (1991) 5.45
Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg (1996) 5.42
Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology (2000) 5.40
Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet (1996) 5.15
Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med (1995) 5.10
Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. Nat Med (1996) 4.87
Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet (1997) 4.86
Simulation of Sahel drought in the 20th and 21st centuries. Proc Natl Acad Sci U S A (2005) 4.70
The use and interpretation of commercial APC gene testing for familial adenomatous polyposis. N Engl J Med (1997) 4.66
Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet (1994) 4.63
Progression model for pancreatic cancer. Clin Cancer Res (2000) 4.60
Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. Science (2000) 4.57
Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res (1997) 4.54
Importance of hospital volume in the overall management of pancreatic cancer. Ann Surg (1998) 4.19
Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res (2001) 4.19
Increased intestinal permeability in patients with Crohn's disease and their relatives. A possible etiologic factor. Ann Intern Med (1986) 4.18
Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet (1996) 4.09
Molecular diagnosis of familial adenomatous polyposis. N Engl J Med (1993) 4.07
PEBP2/PEA2 represents a family of transcription factors homologous to the products of the Drosophila runt gene and the human AML1 gene. Proc Natl Acad Sci U S A (1993) 4.05
Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg (1997) 3.90
Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg (1991) 3.88
Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer (1993) 3.86
An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium. Am J Hum Genet (1995) 3.81
Comparative sequence analysis of a gene-rich cluster at human chromosome 12p13 and its syntenic region in mouse chromosome 6. Genome Res (1998) 3.80
Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res (2000) 3.74
DPC4 gene in various tumor types. Cancer Res (1996) 3.74
Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med (2000) 3.70
Scrambled exons. Cell (1991) 3.65
Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell (1991) 3.59
The sedative component of anesthesia is mediated by GABA(A) receptors in an endogenous sleep pathway. Nat Neurosci (2002) 3.52
Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant (1996) 3.51
Allelotype of pancreatic adenocarcinoma using xenograft enrichment. Cancer Res (1995) 3.33
Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med (1995) 3.31
Conversion of diploidy to haploidy. Nature (2000) 3.28
Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med (2001) 3.27
Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol (2001) 3.27
Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst (1999) 3.26
Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res (1994) 3.25
The APC gene product in normal and tumor cells. Proc Natl Acad Sci U S A (1993) 3.25
Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res (1997) 3.17
Association of low levels of mannan-binding protein with a common defect of opsonisation. Lancet (1989) 3.12
Distal pancreatectomy: indications and outcomes in 235 patients. Ann Surg (1999) 3.09
HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet (2002) 3.07
Genetic instability occurs in the majority of young patients with colorectal cancer. Nat Med (1995) 3.07
PATRIC: the VBI PathoSystems Resource Integration Center. Nucleic Acids Res (2006) 3.06
A major lung cancer susceptibility locus maps to chromosome 6q23-25. Am J Hum Genet (2004) 3.05
The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res (2001) 3.02